论文部分内容阅读
目的观察聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎获得EVR者治疗过程中血清T淋巴细胞亚群的变化,从而了解有效抗病毒治疗对患者细胞免疫状态的影响。方法选取使用聚乙二醇干扰素α-2a 180μg,皮下注射,1次/周联合利巴韦林片900~1200 mg/d,口服,疗程48周抗病毒治疗的慢性丙型肝炎患者中获得早期病毒学应答者46例,分析其T淋巴细胞亚群的变化。结果 CD3+T淋巴细胞在治疗12周时较治疗前下降,但P>0.05,差异无统计学意义,其后CD3+T淋巴细胞呈上升趋势,到治疗48周时与治疗前比较差异有统计学意义(P<0.01)。在治疗过程中CD4+T淋巴细胞、CD4+/CD8+逐渐升高,CD8+T淋巴细胞逐渐下降,治疗48周与治疗开始前比较差异均有显著统计学意义(P<0.01)。治疗48周疗程结束时上述指标与正常对照组相比较P均>0.05。结论通过有效抗病毒治疗,患者细胞免疫功能逐渐接近正常水平。
Objective To observe the changes of serum T lymphocyte subsets during the treatment of chronic hepatitis C patients treated with pegylated interferon alfa-2a and ribavirin to understand the effect of effective antiviral therapy on cellular immune status. Methods Chronic Hepatitis C patients were treated with peginterferon alfa-2a 180μg, subcutaneously and once / week in combination with ribavirin 900 ~ 1200 mg / d orally for 48 weeks. Early virological response in 46 cases, analysis of T lymphocyte subsets. Results CD3 + T lymphocytes decreased at 12 weeks of treatment compared with those before treatment, but there was no significant difference between the two groups (P> 0.05). CD3 + T lymphocytes then showed an upward trend. There was statistical difference between the two groups Significance (P <0.01). CD4 + T lymphocytes, CD4 + / CD8 + cells gradually increased and CD8 + T lymphocytes decreased gradually during the treatment. There was significant difference between the 48th week and the beginning of treatment (P <0.01). At the end of the 48-week treatment, the above indexes were all higher than that of the normal control group (P> 0.05). Conclusion Through effective antiviral therapy, patients with cellular immune function gradually close to normal levels.